Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts’ expectations of $4.37 billion, according to Benzinga Pro.
Revenues increased 11% year-over-year in U.S. dollars or 9% in local currency.
The increase was mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A) and from higher revenues from key innovative products, partially offset by lower proceeds from the sale of certain product rights and lower revenues from the International Markets segment due to the divestment of a business venture in Japan.
The company on Wednesday said that the fourth quarter of 2025 marks the first quarter in which the key brands collectively delivered approximately $1 billion of revenues.
Austedo (Huntington’s disease drug) 2025 sales increased 34% to $2.26 billion, surpassing the management …